<SEC-DOCUMENT>0001140361-23-005580.txt : 20230209
<SEC-HEADER>0001140361-23-005580.hdr.sgml : 20230209
<ACCEPTANCE-DATETIME>20230209172009
ACCESSION NUMBER:		0001140361-23-005580
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230209
DATE AS OF CHANGE:		20230209

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		23607405

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>ny20006859x16_dfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; text-align: left;" bgcolor="#ffffff">
  <div>
    <div></div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="font-size: 14pt;">UNITED STATES<font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font>SECURITIES AND EXCHANGE COMMISSION</font><br>
      <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">SCHEDULE 14A</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Proxy Statement Pursuant to Section&#160;14(a) of the<br>
        Securities Exchange Act of 1934</font> <br>
    </div>
    <div style="font-size: 10pt;"> <br>
    </div>
    <div style="font-size: 10pt;">Filed by the Registrant&#8194;&#8201;&#8201;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="font-size: 10pt;">Filed by a party other than the Registrant&#8194;&#8201;&#8201;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div>&#160;</div>
    <div style="font-size: 10pt;">Check the appropriate box:</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Preliminary Proxy Statement</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Definitive Proxy Statement</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#8194;&#8201;&#8201;Definitive Additional Materials</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Soliciting Material under &#167; 240.14a-12</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">Amarin Corporation plc</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium; border-right: medium; border-top: medium none; margin: 0px auto; height: 2px; width: 100%; color: #000000;" align="center" noshade="noshade"></div>
    <div style="text-align: center; font-size: 10pt;">&#160;(Name of Registrant as Specified In Its Charter)</div>
    <div>
      <div>&#160;</div>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Catapult Fund LLC</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Hawkeye Fund LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">ISP Fund LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Offshore Master Fund LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Master Fund II LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Athena Fund Ltd</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Atom Master Fund LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Fund GP LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Fund GP LLC</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Offshore Fund GP LLC</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Management GP LLC</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Sarissa Capital Management LP</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Alexander J. Denner, Ph.D.</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Patrice Bonfiglio</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Paul Cohen, M.D.<br>
      Mark DiPaolo<br>
      Keith L. Horn<br>
      Odysseas Kostas, M.D.</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Louis Sterling III<br>
      Diane E. Sullivan</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">
      <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>
      <div style="text-align: center; font-size: 10pt;">&#160;(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="font-size: 10pt;">Payment of Filing Fee (Check all boxes that apply):</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#8194;&#8201;&#8201;No fee required</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Fee paid previously with preliminary materials</div>
    <div style="font-size: 10pt;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8194;&#8201;&#8201;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;">This filing contains a press release issued on February 9, 2023 by Sarissa Capital.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 9pt; font-weight: bold;">SARISSA CAPITAL DOES NOT BELIEVE AMARIN CARES ABOUT SHAREHOLDERS</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Vote the <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font> proxy card &#8220;FOR&#8221; the appointment of the Sarissa
      Nominees and &#8220;FOR&#8221; the Removal of Chairman Per Wold-Olsen <u>on or before February 21, 2023</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Greenwich, CT, February 9, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today issued the following letter to other shareholders of Amarin
      Corporation plc (NASDAQ: AMRN):</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Dear Fellow Amarin Shareholders:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We, the owners, face an important decision at our upcoming shareholder meeting. Amarin has an incredibly valuable asset in Vascepa/Vazkepa, but the
      company continues to destroy value by mismanagement and poor capital allocation decisions. The company is in dire need of change, which even current leadership recognizes. And shareholders sent a loud and clear message in support of change at the
      annual meeting. However, the board spends millions of dollars of precious shareholder capital to keep shareholders off the board. Inexplicably, the board does not welcome the positive participation of its largest shareholder with a stellar track
      record of success.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Amarin is at a critical juncture and risks further destruction of value unless we shareholders enact change now. Sarissa is seeking to remake the
      board by adding shareholder representatives who we believe will help maximize shareholder value and by removing Chairman Per Wold-Olsen. Our slate, including Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for
      nearly $10 billion, has the qualifications and experiences to help Amarin reach its true potential.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa urges shareholders to vote the <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font> proxy card &#8220;FOR&#8221; the appointment of
      the Sarissa Nominees and &#8220;FOR&#8221; the Removal of Chairman Per Wold-Olsen <font style="font-weight: bold;"><u>on or before February 21, 2023</u></font>.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">As the general meeting approaches, we ask fellow shareholders separate Amarin&#8217;s words from its actions. As we all know, actions speak louder than
      words. The actions of &#8220;new Amarin&#8221; are marked by the same poor performance, missed goals and blatant disregard for shareholders as the &#8220;old Amarin.&#8221; Amarin&#8217;s words are filled with inaccurate statements, empty promises and a lack of accountability.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin has the audacity to state publicly, &#8220;the Company made solid progress in 2022, against its strategic objectives&#8221; even though
      2022 was terrible for shareholders by any objective measure:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2b9d6027861447d9baa172030a463c9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">In 2022, Amarin&#8217;s stock price declined over 64%, wiping out more than $840 million of shareholder value.*</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z123a8eb48dfb4fac9b36ffa615a0cfa0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">In June 2022, Amarin was 6 months late in announcing cost cuts in the US after a third generic entered and disrupted the market in January 2022. Entrance of the third generic
              was expected. The shareholder capital wasted due to the delay was an immense and avoidable destruction of shareholder value.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e0586b95e5f4f1c818e2f8d4fd02c3e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The European launch is off to a terrible start. Management could not convince Germany to reimburse Vazkepa even though, with the use of Vazkepa, Germany could save a significant
              portion of the &gt;&#8364;28 billion that it spends annually on cardiovascular disease.<sup style="font-family: Roboto, Arial; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup> The rest of Europe is behind schedule, failing to live up to management&#8217;s earlier promises.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s proclamation that its &#8220;Commitment to High Standards of Corporate Governance Drives Alignment and Accountability&#8221; is
      inconsistent with their treatment of shareholders as Amarin has demonstrated time and time again that it dismisses shareholder interests:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bc55ace69584a6b8ba650bebf4d0145" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The board continues to completely ignore the outcome of the most recent annual meeting where nearly 50% of all votes cast were either votes against the Amarin board or
              abstentions.&#160; Notably, this result occurred after Sarissa publicly stated that &#8220;we intend to vote &#8216;ABSTAIN&#8217; as this reinforces our message that change is needed as we give the board time to add shareholder representatives.&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> &#8225;</sup> Yet,
              the board still refuses to add Sarissa representatives.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb79cbd5af4648378c56e448ae687ed4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">We believe the board&#8217;s prolonged &#8220;board refreshment process&#8221; was not legitimate. No shareholder representatives were added to the board and our input was never sought on any of
              their appointees. Sarissa is Amarin&#8217;s largest shareholder, and we have a track record of creating shareholder value through board representation, including in the cardiovascular space. It is bewildering that Amarin remains obstinate and will
              not allow shareholder participation on the board.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z556b527f037f4224afdf72a3cc8b6c75" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin disclosed that it has spent more than $4 MILLION of shareholder capital and is planning to spend &gt;$7 MILLION total to prevent its largest shareholder from obtaining
              representation on the board. This amount is a whopping ~6X more than what Sarissa intends to spend in this proxy contest. Either Amarin does not know how to spend money efficiently or does not care about shareholders&#8217; money.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Amarin&#8217;s assertion that &#8220;New Management Has Made Engagement a Top Priority&#8221; is far from the truth as Amarin continues to make it
      difficult for shareholders, who are frustrated, to have a voice:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93c2112ab03f4d6faf1e772ac6669686" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The board does not engage meaningfully with its shareholder base. Historically, barely 50% of the shareholders show up at any given shareholder meeting. Chairman Wold-Olsen and
              other directors have been dismissive of Amarin&#8217;s shareholders as a &#8220;retail&#8221; shareholder base. &#8220;Retail&#8221; shareholders are owners of Amarin and are entitled to have their voices heard.</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z192e7eb8ee764c4c8f8b7783049c748f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin delayed the disclosure of the record date for the general meeting, artificially established an earlier than necessary cut-off time for voting and delayed delivery of
              crucial shareholder lists requested by Sarissa. We believe Amarin&#8217;s board is employing these tactics to uneven the playing field so that shareholders are unable to voice their dissatisfaction with the current regime. Amarin claims that these
              timelines are all required by UK law, which is canonically false, and they know it!</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e949014a56c4cce92b7265b3b6a5a9a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Amarin has continuously misrepresented its interactions with Sarissa and Sarissa&#8217;s track record of success as it attempts to smear us and our nominees. In our presentations, we
              exposed Amarin&#8217;s misstatements, disinformation, and dishonesty, including by providing detailed accounts of our correspondence. Amarin attempts to sully our track record using wrong and misleading metrics. In fact, the average performance of
              our larger positions during the tenure of Sarissa and Sarissa designees is +39.7%.&#167; In contrast, Amarin&#8217;s performance under CEO Karim Mikhail and Chairman Per Wold-Olsen were -70.8% and -62.8% to year end 2022 respectively.<sup style="font-family: 'Cambria Math', serif; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8214;</sup> Amarin maintains that &#8220;we don&#8217;t need Sarissa to maximize value.&#8221; Again, actions speak louder than words.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Amarin is in dire need of change. Sarissa believes the current regime is wasting a uniquely valuable opportunity. Vascepa is a highly attractive asset
      that can not only meaningfully improve patients&#8217; lives by reducing cardiovascular events but also save significant money for health systems worldwide. The board, led by Chairman Wold-Olsen, has failed shareholders and takes no accountability for its
      failures. Sarissa urges shareholders to act now to support change so that the current leadership does not continue its misguided stewardship of shareholder capital.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We look forward to continuing our engagement with our fellow shareholders. Thank you for your continued support.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa Capital Management LP</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">#FreeAmarin</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Visit our website at <u>www.freeamarin.com</u>&#160;for helpful
      information about Sarissa and the need for change at Amarin.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Vote the <font style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy card &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Sarissa Nominees and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the removal of Chairman Per Wold-Olsen.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, <font style="font-weight: bold;"><u>SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023</u></font>.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Shareholders should be receiving the <font style="font-weight: bold; color: rgb(0, 32, 96); background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy card this week. If you do not
      receive your <font style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 32, 96); font-style: normal; font-variant: normal; text-transform: none;">BLUE</font>&#160;proxy card this week or have any questions on how to vote, please contact:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">D.F. King &amp; Co., Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">48 Wall Street</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">New York, New York 10005</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shareholders call toll-free:</font> (800) 331-7024</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Banks and Brokers call:</font> (212) 269-5550</div>
    <div style="text-align: center; font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">By Email:</font> <u>AMRN@dfking.com</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">* Calculated from end of day December 31, 2021 &#8211; December 30, 2022. Source: Bloomberg</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="font-family: Roboto, Arial; vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup> European Cardiovascular Disease Statistics 2017 edition</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8225; </sup>Sarissa Capital Press Release June 15, 2022: <u>https://www.businesswire.com/news/home/20220615006073/en/Sarissa-Capital-Intends-to-Vote-%E2%80%9CAbstain%E2%80%9D-at-the-Amarin-Annual-Meeting</u></div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#167; Calculated as average price change where a Sarissa or Sarissa-affiliated director held tenure as a board member, for larger Sarissa portfolio
      positions defined as (&#8805;$50M), between the date immediately preceding their first date-in service and 12/30/2022. Not weighted by investment and not indicative of Sarissa&#8217;s investment returns</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8214;</sup> Calculated as price change between the dates 7/30/2021 and 12/30/2022 for CEO Karim Mikhail and 1/7/2022 and 12/30/2022 for Per
      Wold-Olsen</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zced921327b4b4d6995c0da01732bcdb6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Contact:</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Jean Puong</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Sarissa Capital Management LP</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">info@sarissacap.com</div>
          </td>
        </tr>

    </table>
    <br>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Additional Information</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy
      card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the
      &#8220;General Meeting&#8221;). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at
      <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New
      York 10005 (Shareholders can call toll-free: (800) 331-7024).
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
